Skip to Content
 
Center for International Blood and Marrow Transplant Research

MM17-02

Main Content

The impact of bortezomib based induction therapy vs no induction therapy on outcomes for light chain amyloidosis.

Study #: MM17-02

Study Status: Published

Presentation(s)

2020, ASCO (Poster)

Bortezomib-based induction is associated with superior outcomes in light chain amyloidosis patients treated with autologous hematopoietic cell transplantation regardless of plasma cell burden.

Citation

Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A.

Transplantation and Cellular Therapy. 2021, Mar 01: 27(3): 27(3):264.e1-264.e7. doi: 10.1016/j.jtct.2020.11.018. Epub 2020, Dec 21. PMCID:PMC8010222.

PubMed

PMID: 33781533

Abstract